GlucoTrack Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
GCTK$1.39-32.2%Stored close · as of Oct 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| In thousands of US dollars (except stock and per stock amounts) | ||
|---|---|---|
| 2023 | 2022 | |
| Research and development expenses (Note 6) | 4,704 | 1,967 |
| Marketing expenses | 122 | - |
| General and administrative expenses (Note 7) | 2,278 | 2,465 |
| Total operating expenses | 7,104 | 4,432 |
| Operating loss | 7,104 | 4,432 |
| Other expense | - | 14 |
| Finance income, net | (7) | (11) |
| Loss for the year | 7,097 | 4,435 |
| Other comprehensive loss (income): | ||
| Foreign currency translation adjustment | 1 | (23) |
| Comprehensive loss for the year | 7,098 | 4,412 |
| Basic and diluted loss per share (Note 2J) | 0.38 | 0.29 |
| Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share | 20,760,266 | 15,474,600 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.